Voyant Bio

🗓 Founded 2023👥 1 employees
Biotechnology Research🌐 voyant.bio
Website LinkedIn
Cancer immunotherapy fails in 80% of patients due to break down in immune cell interactions. Voyant Bio has developed a spatial biology platform to enhance immunity against multiple cancers by rewiring immune cell interactions. Voyant’s platform has the potential to radically improve treatment efficacy for over a third of the patients who fail to respond to current cancer immunotherapies, representing an $100B+ opportunity.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Voyant Bio founded?
Voyant Bio was founded in 2023.
What industry is Voyant Bio in?
Voyant Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.